The Need for an HIV Vaccine in the Era of Highly Effective PrEP
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "HIV Vaccines".
Deadline for manuscript submissions: 31 August 2025 | Viewed by 117
Special Issue Editors
Interests: HIV prevention; health inequities; qualitative methods; trauma-informed care
Interests: HIV prevention; HIV vaccines; tuberculosis; vaccines; immunology; clinical trials; clinical infectious disease
Special Issue Information
Dear Colleagues,
There is still a need for an HIV vaccine, even though there are effective HIV prevention options like pre-exposure prophylaxis (PrEP). This Special Issue aims to thoroughly examine the landscape of HIV prevention with an emphasis on the critical role of an HIV vaccine in bringing an end to the HIV epidemic. It will encompass the extensive impact of HIV vaccine research infrastructure, ongoing initiatives in HIV vaccine research, and the strategic direction for future research in this field.
Dr. Michele Peake Andrasik
Dr. William O. Hahn
Dr. Susan P. Buchbinder
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HIV
- vaccines
- HIV prevention
- bnAbs
- clinical trials
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
